Bleomycin sulfateBleomycin sulfate
MedChemExpress (MCE)
HY-17565
9041-93-4
Bleomycin sulfate
99.62%
4°C, sealed storage, away from moisture *In solvent : -80°C, 2 years
-20°C, 1 year (sealed storage, away from moisture)
Room temperature in continental US
may vary elsewhere.
Bleomycin sulfate is a DNA synthesis inhibitor. Bleomycin hydrochloride is a DNA damaging agent. Bleomycin sulfate is an antitumor antibiotic.
Bleomycin (BLM) sulfate is chosen as the best-studied micronucleus (MN) inducers in human lymphocytes with different mechanisms of genotoxicity. The most frequent Bleomycin-induced DNA lesions are single and double strand breaks and single apuinic/apyrimidinic sites. At the same time Bleomycin is true radiomimetic compound, resembling almost completely the genetic effect of ionizing radiation[1]. The IC50 value of Bleomycin sulfate for UT-SCC-19A cell line is 4.0±1.3 nM. UT-SCC-12A and UT-SCC-12B are both more resistant to Bleomycin (BLM)
IC50 values are 14.2±2.8 nM and 13.0±1.1 nM, respectively[2]. Bleomycin sulfate (50, 100 μM
for 24, 48 h) induce pulmonary fibrosis in RLE-6TN cell (50 μM) and A549 cell (100 μM)[4].
Bleomycin sulfate can be used to induce pulmonary fibrosis models. After administration via intramuscular, subcutaneous, intraperitoneal, or intrapleural routes, Bleomycin sulfate is rapidly absorbed and reaches peak plasma concentrations in approximately 60 minutes. Less than 1% of intravenously injected Bleomycin sulfate binds to plasma proteins, ensuring high bioavailability. The mean plasma clearance rate of Bleomycin sulfate is about 70 mL/min/m2, indicating high plasma elimination and urinary excretion rates2[6]. .f12{ font-size: 12px
} .fwb{ font-weight: bold
} .lh22{ line-height: 22px
} .lh23 { line-height: 23px
} .pl13{ padding-left: 13px
} .part { margin-top: 18px
} .mold-first-tit { width: 100%
height: 44px
line-height: 44px
background: #F9F7FB
border-bottom: 1px solid #EBE4F6
padding-left: 16px
box-sizing: border-box
margin-bottom: 17px
} .mold-second-tit:before { content:"
width: 6px
height: 6px
display: inline-block
border-radius: 50%
background: rgba(255,102,0,0.4)
margin-right: 12px
position: relative
top: -3px
} .lft-border { border-left: 1px dotted #EBE4F6
padding-right: 12px
margin-left: 3px
box-sizing: border-box
padding-bottom: 12px
} /* .part .dec:last-child { border-bottom: 0
} */ .dec { margin: 10px 15px 0
padding-bottom: 10px
border-bottom: 1px dashed #EBE4F6
} .btm-border { border-left: 1px dashed #EBE4F6
} .text-bg { margin-top: 10px
background: #FFFBF1
padding: 14px
border-bottom: 0
position: relative
} .text-note-bg { margin-top: 10px
background: #FFFDF7
padding: 12px
border-bottom: 0
position: relative
} .text-note { width: 51px
height: 20px
line-height: 20px
background: #FFE2AA
text-align: center
border-radius: 0 0 8px 0
position: absolute
top: 0
left: 0
} .text-note-dec { margin-top: 15px
} Induction of Pulmonary Fibrosis[7] Background Bleomycin sulfate can lead to lung patchy parenchymal inflammation, epithelial cell injury with reactive hyperplasia, epithelial-mesenchymal transition, activation and differentiation of fibroblasts to myofibroblasts, and basement membrane and alveolar epithelium injures. The experimental use of Bleomycin sulfate is to induce pulmonary fibrosis animal models. Specific Mmodeling Methods Mice: C57BL/6 • 12-week-oldAdministration: 3-5 mg/kg • intratracheal administration • sprays on day one Note The mice were housed in separate stainless-steel cages (six mice per cage) in a temperature-controlled environment (20-24°C) on 12 h light-dark cycles with unrestricted access to food and water. Modeling Indicators Body quality changes: The appetite activity is reduced, with the fur less shiny, the spirits being lethargic, and the bodyweight decreasing. Showed shortness of breath, coughing, and noisy.Lung changes: Increased fibrotic consolidations, non-aerated lung area, and high-density lung area. Pulmonary function decreased.Molecular changes: Increased indicators: TGF-β1, TNF-α, IL-6, and GM-CSF in bronchoalveolar lavage fluid. Correlated Product(s): Bleomycin hydrochloride (HY-17565A) Opposite Product(s): Neotuberostemonine (HY-N3196)
DNA/RNA Synthesis[1] In Vitro Bleomycin (BLM) sulfate is chosen as the best-studied micronucleus (MN) inducers in human lymphocytes with different mechanisms of genotoxicity. The most frequent Bleomycin-induced DNA lesions are single and double strand breaks and single apuinic/apyrimidinic sites. At the same time Bleomycin is true radiomimetic compound, resembling almost completely the genetic effect of ionizing radiation[1]. The IC50 value of Bleomycin sulfate for UT-SCC-19A cell line is 4.0±1.3 nM. UT-SCC-12A and UT-SCC-12B are both more resistant to Bleomycin (BLM)
IC50 values are 14.2±2.8 nM and 13.0±1.1 nM, respectively[2]. Bleomycin sulfate (50, 100 μM
for 24, 48 h) induce pulmonary fibrosis in RLE-6TN cell (50 μM) and A549 cell (100 μM)[4]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> Bleomycin sulfate Related Antibodies
| | | |
| | | | | |
[1]. Hovhannisyan G, et al. Comparative analysis of individual chromosome involvement in micronuclei induced by bleomycin in human leukocytes. Mol Cytogenet. 2016 Jun 21
9:49. [Content Brief]
[2]. Jaaskela-Saari HA, et al. Squamous cell cancer cell lines: sensitivity to bleomycin and suitability for animal xenograft studies. Acta Otolaryngol Suppl. 1997
529:241-4. [Content Brief]
[3]. Corboz MR, et al. Therapeutic administration of inhaled INS1009, a treprostinil prodrug formulation, inhibits bleomycin-induced pulmonary fibrosis in rats. Pulm Pharmacol Ther. 2018 Apr
49:95-103. [Content Brief]
[4]. Ling Peng, et al. Scutellarin ameliorates pulmonary fibrosis through inhibiting NF-κB/NLRP3-mediated epithelial-mesenchymal transition and inflammation. Cell Death Dis. 2020 Nov 13
11(11):978. [Content Brief]
[5]. Kang Miao, et al. Scutellarein inhibits BLM-mediated pulmonary fibrosis by affecting fibroblast differentiation, proliferation, and apoptosis. Ther Adv Chronic Dis. 2020 Jul 30
11:2040622320940185. [Content Brief]
[6]. Brandt JP, et, al. Bleomycin. National Library of Medicine. August 28, 202
[7]. Gul A, et, al. Pulmonary fibrosis model of mice induced by different administration methods of bleomycin. BMC Pulm Med. 2023 Mar 21
23(1):91. [Content Brief]
